Abstract 1091P
Background
Although immune checkpoint inhibitors (ICIs) have significantly changed the treatment algorithm of patients with advanced non-small cell lung cancer (aNSCLC), the discovery of clinically useful biomarkers remain a challenging issue. Recently, a new score, Patras Immunotherapy Score (PIOS), has been proposed by our group focusing on the results of aNSCLC patients treated with nivolumab or pembrolizumab. The aim of the current study was to investigate the prognostic and predictive value of PIOS in aNSCLC patients treated with combination of immunotherapy with chemotherapy.
Methods
PIOS score is calculated as PS×BMI/LOT×AGE with PS representing the Performance Status, BMI Body Mass Index, LOT Line Of Treatment and AGE the age at diagnosis. In the current study, 189 patients with confirmed aNSCLC, who were treated with chemotherapy combined with immunotherapy, were finally enrolled in order to investigate the prognostic value of PIOS. To assess specificity of PIOS for immunotherapy, a second group with 513 aNSCLC patients, treated with chemotherapy alone, were also retrospectively included.
Results
PIOS was associated with survival in terms of progression free survival (PFS) and overall survival (OS). In particular, higher PIOS score was related to improved PFS not only in univariate (ΗR 0.56, p=0.015), but also in multivariable analysis using as co-factor the PD-L1 expression (HR 0.53, p=0.012). Furthermore, PIOS score was also associated with OS (p=0.002). The favorable group with higher PIOS had median OS of 1067 days compared to 528 days for the unfavorable group with low PIOS score (HR 0.39, p<0.001) at univariate analysis, while this association remained significant in multivariable analysis (HR 0.43, p=0.001). Predictiveness of PIOS for patients treated with immunotherapy was confirmed in the combined analysis of both subgroups of patients (n=189 + 513) with a significant interaction between PIOS and the specific treatment being observed (HR = 0.066 with p<0.001).
Conclusions
This study confirmed the prognostic value as well as the predictive value of PIOS formula in aNSCLC patients treated with immunotherapy/chemotherapy combination.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.